Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma

被引:3
作者
Dreher, Rachel D. [1 ,2 ]
Theisen, Emily R. [1 ,2 ,3 ]
机构
[1] Nationwide Childrens Hosp, Abigail Wexner Res Inst, Ctr Childhood Canc & Blood Dis, Columbus, OH 43205 USA
[2] Ohio State Univ, Coll Med, Biomed Sci Grad Program, Columbus, OH 43210 USA
[3] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA
来源
FRONTIERS IN ONCOLOGY | 2023年 / 12卷
关键词
LSD1; sarcoma; mesenchymal development; oncogenic fusion protein; epigenetics; LSD1 HISTONE DEMETHYLASE; EWING SARCOMA; NEURONAL DIFFERENTIATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GENE; DEACETYLASE; INHIBITION; MECHANISM; COREST;
D O I
10.3389/fonc.2022.1076581
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sarcomas are a diverse group of tumors with numerous oncogenic drivers, and display varied clinical behaviors and prognoses. This complexity makes diagnosis and the development of new and effective treatments challenging. An incomplete understanding of both cell of origin and the biological drivers of sarcomas complicates efforts to develop clinically relevant model systems and find new molecular targets. Notably, the histone lysine specific demethylase 1 (LSD1) is overexpressed in a number of different sarcomas and is a potential therapeutic target in these malignancies. With the ability to modify histone marks, LSD1 is a key player in many protein complexes that epigenetically regulate gene expression. It is a largely context dependent enzyme, having vastly different and often opposing roles depending on the cellular environment and which interaction partners are involved. LSD1 has been implicated in the development of many different types of cancer, but its role in bone and soft tissue sarcomas remains poorly understood. In this review, we compiled what is known about the LSD1 function in various sarcomas, to determine where knowledge is lacking and to find what theme emerge to characterize how LSD1 is a key molecular driver in bone and soft tissue sarcoma. We further discuss the current clinical landscape for the development of LSD1 inhibitors and where sarcomas have been included in early clinical trials.
引用
收藏
页数:16
相关论文
共 110 条
[21]   Rare cancers are not so rare: The rare cancer burden in Europe [J].
Gatta, Gemma ;
van der Zwan, Jan Maarten ;
Casali, Paolo G. ;
Siesling, Sabine ;
Dei Tos, Angelo Paolo ;
Kunkler, Ian ;
Otter, Renee ;
Licitra, Lisa ;
Mallone, Sandra ;
Tavilla, Andrea ;
Trama, Annalisa ;
Capocaccia, Riccardo .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (17) :2493-2511
[22]  
GlaxoSmithKline, 2019, PHAS OP LAB DOS ESC
[23]   Biological roles of LSD1 beyond its demethylase activity [J].
Gu, Feiying ;
Lin, Yuxin ;
Wang, Zhun ;
Wu, Xiaoxin ;
Ye, Zhenyue ;
Wang, Yuezhen ;
Lan, Huiyin .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2020, 77 (17) :3341-3350
[24]   Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells [J].
Haydn, Tinka ;
Kehr, Sarah ;
Willmann, Dominica ;
Metzger, Eric ;
Schuele, Roland ;
Fulda, Simone .
INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (12) :3435-3449
[25]   Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells [J].
Haydn, Tinka ;
Metzger, Eric ;
Schuele, Roland ;
Fulda, Simone .
CELL DEATH & DISEASE, 2017, 8 :e2879-e2879
[26]   LSD1 Mediates Neuronal Differentiation of Human Fetal Neural Stem Cells by Controlling the Expression of a Novel Target Gene, HEYL [J].
Hirano, Kazumi ;
Namihira, Masakazu .
STEM CELLS, 2016, 34 (07) :1872-1882
[27]  
Hollebecque A, 2019, ANN ONCOL, V30
[28]   Epidemiology and Etiology of Sarcomas [J].
Hui, Jane Y. C. .
SURGICAL CLINICS OF NORTH AMERICA, 2016, 96 (05) :901-+
[29]  
Imago BioSciences Inc, 2022, MULT OP LAB STUD ASS
[30]  
Incyte Corporation, 2020, OP LAB PHAS 1B STUD